K
12.33
1.05 (9.31%)
| Previous Close | 11.28 |
| Open | 11.99 |
| Volume | 4,051,395 |
| Avg. Volume (3M) | 1,833,754 |
| Market Cap | 1,096,884,352 |
| Price / Sales | 12.90 |
| Price / Book | 20.72 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2026 |
| Profit Margin | -267.52% |
| Operating Margin (TTM) | -458.61% |
| Diluted EPS (TTM) | -2.09 |
| Total Debt/Equity (MRQ) | 5.31% |
| Current Ratio (MRQ) | 8.07 |
| Operating Cash Flow (TTM) | 111.23 M |
| Levered Free Cash Flow (TTM) | -95.01 M |
| Return on Assets (TTM) | -19.60% |
| Return on Equity (TTM) | -41.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Kura Oncology, Inc. | Mixed | Bullish |
AIStockmoo Score
-1.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -1.00 |
|
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.09% |
| % Held by Institutions | 93.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Prosight Management, Lp | 30 Jun 2026 | 2,021,964 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |